Loading...

Steven Batki, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentPsychiatry
Address4150 Clement Street
San Francisco CA 94121
Phone415-221-4810 ext. 23671
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine

    Collapse Overview 
    Collapse Overview
    Steven L. Batki, M.D. is Professor of Psychiatry, in Residence, at the University of California, San Francisco (UCSF) School of Medicine and Chief of the Substance Abuse Programs and Director of the Addiction Psychiatry Research Program at the San Francisco VA Medical Center (SFVAMC), where he also directs the UCSF Addiction Psychiatry Fellowship Program. Dr. Batki is engaged in addiction research, training, and clinical services.

    Dr. Batki’s research and clinical interests include pharmacologic treatment for addiction to alcohol, opioids, and stimulants. His work focuses on psychiatric and medical disorders that co-occur with addiction, such as such as PTSD, traumatic brain injury (TBI), schizophrenia, and HIV/HCV. He has published extensively on clinical research in addiction and co-occurring disorders. He chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37, Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43, Medication-Assisted Treatment for Opioid Dependence.

    Dr. Batki's current research is supported by the Department of Defense and NIDA. His DoD projects are examining the effectiveness of pharmacotherapy for alcohol use disorders in veterans with posttraumatic stress disorder (PTSD) as well as in veterans with mild traumatic brain injury (TBI). Dr. Batki is also conducting NIDA-funded research on the pharmacotherapy of methamphetamine dependence. Recently completed NIDA and NIAAA work has included the study of hepatitis C treatment in injection drug users and the pharmacological treatment of alcohol dependence in schizophrenia.


    Collapse Research 
    Collapse Research Activities and Funding
    Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r
    NIH/NIDA R01DA034527Feb 1, 2013 - Jan 31, 2018
    Role: Co-Principal Investigator
    Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B
    NIH/NIDA R01DA031678Jun 1, 2011 - Jan 31, 2017
    Role: Co-Principal Investigator
    Improving Hepatitis C Treatment in Injection Drug Users
    NIH/NIDA R01DA016764Sep 26, 2003 - Jun 30, 2010
    Role: Principal Investigator
    Naltrexone Treatment of Alcohol Abuse in Schizophrenia
    NIH/NIAAA R01AA013655Apr 1, 2003 - Mar 31, 2009
    Role: Principal Investigator
    PHARMACOTHERAPY OF METHAMPHETAMINE DEPENDENCE
    NIH/NIDA R01DA011397Feb 20, 1998 - Dec 31, 2002
    Role: Principal Investigator
    Treatment for Complex Patients: Continuing and Extended Care
    NIH/NIDA P50DA009253Sep 29, 1994 - May 31, 2015
    Role: Co-Investigator
    TUBERCULOSIS CHEMOPROPHYLAXIS IN INJECTION DRUG USERS
    NIH/NIDA R01DA008526Aug 1, 1994 - Jun 30, 1998
    Role: Principal Investigator
    DRUG DEPENDENCE CLINICAL RESEARCH PROGRAM
    NIH/NIDA P50DA001696Feb 1, 1978 - Aug 31, 2000
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Zaman T, Rife TL, Batki SL, Pennington DL. An Electronic Intervention to Improve Safety for Pain Patients Co-Prescribed Chronic Opioids and Benzodiazepines. Subst Abus. 2018 Mar 29; 1-31. PMID: 29595408.
      View in: PubMed
    2. Herbst E, Pennington D, Kuhn E, McCaslin SE, Delucchi K, Batki SL, Dickter B, Carmody T. Mobile Technology for Treatment Augmentation in Veteran Smokers With Posttraumatic Stress Disorder. Am J Prev Med. 2018 Jan; 54(1):124-128. PMID: 29074319.
      View in: PubMed
    3. Coffin PO, Santos GM, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki SL. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Addiction. 2018 Feb; 113(2):268-278. PMID: 28734107.
      View in: PubMed
    4. Turner CM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Batki S, Santos GM. Race/ethnicity, education, and age are associated with engagement in ecological momentary assessment text messaging among substance-using MSM in San Francisco. J Subst Abuse Treat. 2017 04; 75:43-48. PMID: 28237053.
      View in: PubMed
    5. Seal KH, Maguen S, Bertenthal D, Batki SL, Striebel J, Stein MB, Madden E, Neylan TC. Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder. J Clin Psychiatry. 2016 Sep; 77(9):1182-1188. PMID: 27035058.
      View in: PubMed
    6. Heinz AJ, Pennington DL, Cohen N, Schmeling B, Lasher BA, Schrodek E, Batki SL. Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder. Mil Med. 2016 07; 181(7):663-71. PMID: 27391620.
      View in: PubMed
    7. Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl). 2016 07; 233(13):2571-80. PMID: 27137199.
      View in: PubMed
    8. Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. J Acquir Immune Defic Syndr. 2016 May 01; 72(1):21-30. PMID: 26674372; PMCID: PMC4837026 [Available on 05/01/17].
    9. Batki SL. What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia? J Clin Psychiatry. 2015 Oct; 76(10):e1336-7. PMID: 26528663.
      View in: PubMed
    10. Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015 Oct; 69:150-7. PMID: 26343607.
      View in: PubMed
    11. Kaplan KA, McQuaid J, Batki SL, Rosenlicht N. Behavioral treatment of insomnia in early recovery. J Addict Med. 2014 Nov-Dec; 8(6):395-8. PMID: 25369939.
      View in: PubMed
    12. Pennington DL, Abé C, Batki SL, Meyerhoff DJ. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res. 2014 Dec 30; 224(3):281-7. PMID: 25444536; PMCID: PMC4254450.
    13. Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014 Aug; 38(8):2169-77. PMID: 25092377; PMCID: PMC4146719.
    14. Kalapatapu RK, Ho J, Cai X, Vinogradov S, Batki SL, Mohr DC. Cognitive-behavioral therapy in depressed primary care patients with co-occurring problematic alcohol use: effect of telephone-administered vs. face-to-face treatment-a secondary analysis. J Psychoactive Drugs. 2014 Apr-Jun; 46(2):85-92. PMID: 25052784; PMCID: PMC4110640.
    15. Batki SL, Pennington DL. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry. 2014 Apr; 171(4):391-4. PMID: 24687193.
      View in: PubMed
    16. Kalapatapu RK, Delucchi KL, Lasher BA, Vinogradov S, Batki SL. Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder. Mil Med. 2013 Sep; 178(9):974-80. PMID: 24005546; PMCID: PMC3815580.
    17. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013 Apr; 33(2):243-7. PMID: 23422399.
      View in: PubMed
    18. Wamsley MA, Julian KA, O'Sullivan P, McCance-Katz EF, Batki SL, Satre DD, Satterfield J. Team-based learning exercise efficiently teaches brief intervention skills to medicine residents. Subst Abus. 2013; 34(4):344-9. PMID: 24159904.
      View in: PubMed
    19. Kalapatapu RK, Lewis DF, Vinogradov S, Batki SL, Winhusen T. Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders. J Addict Dis. 2013; 32(2):206-16. PMID: 23815427; PMCID: PMC3703837.
    20. Satterfield JM, O'Sullivan P, Satre DD, Tsoh JY, Batki SL, Julian K, McCance-Katz EF, Wamsley M. Using standardized patients to evaluate screening, brief intervention, and referral to treatment (SBIRT) knowledge and skill acquisition for internal medicine residents. Subst Abus. 2012; 33(3):303-7. PMID: 22738010.
      View in: PubMed
    21. Meszaros ZS, Dimmock JA, Ploutz-Snyder R, Chauhan SV, Abdul-Malak Y, Middleton FA, Batki SL. Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res. 2011 Nov; 132(2-3):190-3. PMID: 21852074; PMCID: PMC3195925.
    22. Meszaros ZS, Dimmock JA, Ploutz-Snyder RJ, Abdul-Malak Y, Leontieva L, Canfield K, Batki SL. Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. Am J Addict. 2011 Sep-Oct; 20(5):462-7. PMID: 21838846; PMCID: PMC3156655.
    23. Batki SL, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment. Am J Addict. 2011 Jul-Aug; 20(4):312-8. PMID: 21679262; PMCID: PMC4651620.
    24. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R, Levine RA. Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study. J Addict Dis. 2010 Jul; 29(3):359-69. PMID: 20635285; PMCID: PMC4651622.
    25. Funderburk JS, Sugarman DE, Maisto SA, Ouimette P, Schohn M, Lantinga L, Wray L, Batki S, Nelson B, Coolhart D, Strutynski K. The description and evaluation of the implementation of an integrated healthcare model. Fam Syst Health. 2010 Jun; 28(2):146-60. PMID: 20695672.
      View in: PubMed
    26. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010 Jun; 69(6):578-92. PMID: 20565449; PMCID: PMC2883750.
    27. Raza S, Siddiqui UA, Megna JL, Schwartz TL, Batki SL. Pregabalin treatment of anxiety in patients with substance use disorders. Ann Pharmacother. 2010 May; 44(5):937-8. PMID: 20388860.
      View in: PubMed
    28. Canfield KM, Smyth E, Batki SL. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse. 2010 Mar; 45(4):496-514. PMID: 20141461.
      View in: PubMed
    29. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug Alcohol Depend. 2009 May 01; 101(3):176-82. PMID: 19233573.
      View in: PubMed
    30. Leontieva L, Dimmock J, Cavallerano M, DeRycke S, Meszaros Z, Carey K, Ploutz-Snyder R, Batki SL. Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. Am J Drug Alcohol Abuse. 2009; 35(5):273-8. PMID: 19591067; PMCID: PMC4651625.
    31. Batki SL, Meszaros ZS, Strutynski K, Dimmock JA, Leontieva L, Ploutz-Snyder R, Canfield K, Drayer RA. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2009 Feb; 107(2-3):139-46. PMID: 19022627; PMCID: PMC2649875.
    32. Batki SL, Leontieva L, Dimmock JA, Ploutz-Snyder R. Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia. Schizophr Res. 2008 Oct; 105(1-3):201-7. PMID: 18701256; PMCID: PMC2582942.
    33. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008 Apr 01; 94(1-3):199-206. PMID: 18243585; PMCID: PMC2821580.
    34. Leontieva L, Dimmock JA, Gately PW, Gallinger L, Ploutz-Snyder R, Batki SL. Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatr Serv. 2008 Mar; 59(3):310-4. PMID: 18308913.
      View in: PubMed
    35. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16. PMID: 18840032.
      View in: PubMed
    36. Batki SL, Dimmock JA, Wade M, Gately PW, Cornell M, Maisto SA, Carey KB, Ploutz-Snyder R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict. 2007 Jul-Aug; 16(4):253-9. PMID: 17661192.
      View in: PubMed
    37. Carey KB, Leontieva L, Dimmock J, Maisto SA, Batki SL. Adapting Motivational Interventions for Comorbid Schizophrenia and Alcohol Use Disorders. Clin Psychol (New York). 2007 Mar; 14(1):39-57. PMID: 19081784.
      View in: PubMed
    38. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007 Apr 17; 88(1):54-63. PMID: 17056206; PMCID: PMC1976289.
    39. Alleyne S, Alao A, Batki SL. Lamotrigine-associated rash and blood dyscrasias in a methadone-treatment patient with hepatitis C. Psychosomatics. 2006 May-Jun; 47(3):257-8. PMID: 16684944.
      View in: PubMed
    40. Manfredi L, Shupe J, Batki SL. Rural jail telepsychiatry: a pilot feasibility study. Telemed J E Health. 2005 Oct; 11(5):574-7. PMID: 16250821.
      View in: PubMed
    41. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39. PMID: 16184072.
      View in: PubMed
    42. Harris DS, Batki SL, Berger SP. Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cues. Am J Drug Alcohol Abuse. 2004 Nov; 30(4):765-82. PMID: 15624548.
      View in: PubMed
    43. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2004 Oct-Dec; 13(5):461-70. PMID: 15764424.
      View in: PubMed
    44. Escamilla MA, Batki S, Reus VI, Spesny M, Molina J, Service S, Vinogradov S, Neylan T, Mathews C, Meza L, Gallegos A, Montero AP, Cruz ML, Neuhaus J, Roche E, Smith L, Leon P, Freimer NB. Comorbidity of bipolar disorder and substance abuse in Costa Rica: pedigree- and population-based studies. J Affect Disord. 2002 Sep; 71(1-3):71-83. PMID: 12167503.
      View in: PubMed
    45. Batki SL. Review: antidepressants are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. PMID: 12180449.
      View in: PubMed
    46. Batki SL. Review: dopamine agonists are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. PMID: 12180450.
      View in: PubMed
    47. Ophoff RA, Escamilla MA, Service SK, Spesny M, Meshi DB, Poon W, Molina J, Fournier E, Gallegos A, Mathews C, Neylan T, Batki SL, Roche E, Ramirez M, Silva S, De Mille MC, Dong P, Leon PE, Reus VI, Sandkuijl LA, Freimer NB. Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet. 2002 Sep; 71(3):565-74. PMID: 12119601; PMCID: PMC379193.
    48. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002 May 01; 66(3):283-93. PMID: 12062463.
      View in: PubMed
    49. Masson CL, Sorensen JL, Batki SL, Okin R, Delucchi KL, Perlman DC. Medical service use and financial charges among opioid users at a public hospital. Drug Alcohol Depend. 2002 Mar 01; 66(1):45-50. PMID: 11850135.
      View in: PubMed
    50. Delucchi KL, Batki SL, Moon J, Jacob P, Jones RT. Urine toxicology samples in cocaine treatment trials: how many need to be tested? J Addict Dis. 2002; 21(2):17-26. PMID: 11916369.
      View in: PubMed
    Steven's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _